A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Trial Profile

A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Fasinumab (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Planned number of patients changed from 10000 to 7000.
    • 26 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2016 Status changed from planning to not yet recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top